<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor superfamily members, including Fas ligand and TRAIL, have been studied extensively for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy, including as components of gene therapy </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the use of FasL expression to achieve <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-selective replication of an oncolytic poxvirus (vFasL), and explored its biology and therapeutic efficacy for FasR- and FasR+ <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> of FasR+ <z:mpath ids='MPATH_458'>normal</z:mpath> and MC38 <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells by vFasL led to abortive <z:mp ids='MP_0001799'>viral</z:mp> replication owing to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and subsequently showed both reduced pathogenicity in non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice and reduced efficacy in FasR+ <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> of FasR- B16 <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells by vFasL led to efficient <z:mp ids='MP_0001799'>viral</z:mp> replication, followed by late induction of FasR and subsequent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with vFasL as compared with its parental virus (vJS6) led to increased <z:mp ids='MP_0010537'>tumor regression</z:mp> and prolonged survival of mice with FasR- <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (B16) but not with FasR+ <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (MC38) </plain></SENT>
<SENT sid="5" pm="."><plain>The delayed induction of FasR by <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in FasR- cells provides for potential increased efficacy beyond the limit of the direct oncolytic effect </plain></SENT>
<SENT sid="6" pm="."><plain>FasR induction provides one mechanism for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-selective replication of oncolytic poxviruses in FasR- <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with enhanced safety </plain></SENT>
<SENT sid="7" pm="."><plain>The overall result is both a safer and more effective oncolytic virus for FasR- <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>